Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glenmark Steps Closer To First NCE With Positive Phase II Data For Crofelemer; Gears Up For Larger Trials

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Years of racing to put an original compound into the market looks set to be one step closer for India's Glenmark Pharmaceuticals as the company announced successful completion of Phase II multi-center clinical trials in India for its first-in-class anti-diarrheal agent crofelemer

You may also be interested in...

Following U.S. FDA Approval, Glenmark Plans Multi-Geography Launches For Crofelemer

India’s Glenmark has sped up its regulatory filings in a large set of countries, enthused by the prospects of filling unmet needs for HIV treatment regimens.

Glenmark Plays Down Napo’s Deal Termination For Crofelemer; Expects Launch In 12-18 Months

India’s Glenmark will go ahead with filing crofelemer NDA despite conflict with its partner Napo Pharmaceuticals, which cancelled the development partnership

MNC Exodus Continues As Lilly India Head Sandeep Gupta Leaves For Glenmark Pharma

Following a recent trend in emerging markets, Eli Lilly’s India Head shifts to Glenmark

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts